Gilead Sciences has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma ...
Material analysis conducted by the Leading Global Fumed Silica Manufacturer (LGFSM) confirmed several notable improvements in the fumed silica produced during Phase 1 Test #5 compared to Test #4: With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results